All In Biotech

Drug Trial Radar · NCT01202188

A Study to Assess the Efficacy, Safety and Tolerability of Once-daily (q.d.) QVA149 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

A 26-week Treatment Multi-center, Randomized, Double-blind, Parallel-group, Placebo and Active Controlled (Open Label) Study to Assess the Efficacy, Safety and Tolerability of QVA149 (110/50 μg q.d.) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

Last checked: Nov 19, 2026Latest source record: Sep 9, 2013 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 2,144 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

2,144

Actual

Start

Sep 2010

Primary completion

Feb 2012

Study completion Mar 2012

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Sep 15, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 40 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to provide pivotal efficacy and safety data for QVA149 in patients with moderate to severe COPD.

Conditions

  • Chronic Obstructive Pulmonary Disease (COPD)

Interventions

  • indacaterol and glycopyrronium (QVA149)Drug

    Capsules for inhalation delivered via SDDPI.

  • glycopyrronium (NVA237)Drug

    Capsules for inhalation delivered via SDDPI.

  • indacaterol (QAB149)Drug

    Capsules for inhalation delivered via SDDPI.

  • tiotropiumDrug

    Capsules for inhalation delivered via HandiHaler® device.

  • placeboDrug

    Placebo to match capsules for inhalation delivered via SDDPI.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Trough Forced Expiratory Volume In One Second (FEV1) After 26 Weeks of TreatmentTime frame: 23 hours 15 minutes and 23 hour 45 minute post-dose Week 26

Locations

166 sites in 19 countries. Site status is shown where the registry gives one.

  • Novartis Investigative Site

    Fullerton, California

  • Novartis Investigative Site

    Riverside, California

  • Novartis Investigative Site

    St. Petersburg, Florida

  • Novartis Investigative Site

    Troy, Michigan

  • Novartis Investigative Site

    Minneapolis, Minnesota

  • Novartis Investigative Site

    Saint Charles, Missouri

  • Novartis Investigative Site

    St Louis, Missouri

  • Novartis Investigative Site

    Omaha, Nebraska

  • Novartis Investigative Site

    Charlotte, North Carolina

  • Novartis Investigative Site

    Columbus, Ohio

  • Novartis Investigative Site

    Medford, Oregon

  • Novartis Investigative Site

    Portland, Oregon

  • Novartis Investigative Site

    Greenville, South Carolina

  • Novartis Investigative Site

    Johnson City, Tennessee

  • Novartis Investigative Site

    Daw Park, Australia

  • Novartis Investigative Site

    Glebe, Australia

  • Novartis Investigative Site

    Kogarah, Australia

  • Novartis Investigative Site

    Nedlands, Australia

  • Novartis Investigative site

    New Lambton, Australia

  • Novartis Investigative Site

    Pleven, Bulgaria

  • Novartis Investigative Site

    Rousse, Bulgaria

  • Novartis Investigative Site

    Sofia, Bulgaria

  • Novartis Investigative Site

    Stara Zagora, Bulgaria

  • Novartis Investigative Site

    Varna, Bulgaria

  • Novartis Investigative Site

    Vancouver, British Columbia, Canada

  • Novartis Investigative Site

    Burlington, Ontario, Canada

  • Novartis Investigative Site

    Courtice, Ontario, Canada

  • Novartis Investigative Site

    Mississuaga, Ontario, Canada

  • Novartis Investigative Site

    Ottawa, Ontario, Canada

  • Novartis Investigative Site

    Toronto, Ontario, Canada

  • Novartis Investigative Site

    Montreal, Quebec, Canada

  • Novartis Investigative Site

    Beuvry, France

  • Novartis Investigative Site

    Bourges, France

  • Novartis Investigative Site

    Ferolles-Attily, France

  • Novartis Investigative Site

    Rennes, France

  • Novartis Investigative Site

    Berlin, Germany

  • Novartis Investigative Site

    Erfurt, Germany

  • Novartis Investigative Site

    Geesthacht, Germany

  • Novartis Investigative Site

    Hanover, Germany

  • Novartis Investigative Site

    Leipzig, Germany

Showing 40 of 166 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.